UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 HARVARD BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation) Delaware 001-33957 04-3306140 (Commission File Number) (I.R.S. Employer Identification No.) 84 October Hill Road Holliston, MA 01746 (Address of Princ ...

Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) stock rose Friday after the company said it will reshape its production footprint across the U.S. and abroad.Harvard Bioscience aims to streamline operations and cut long-term costs.Facility ChangesThe company plans to close its Holliston, Massachusetts, plant. U.S. output will shift to its Minneapolis, Minnesota, hub. Some work will move to sites in Germany, Sweden, and the U.K.CEO John Duke said the reorganization builds on flexibility from recent refinancing. He sai ...

Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028 while improving throughput and execution HOLLISTON, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced a strategic consolidation of its manufacturing operations designed ...

Core Viewpoint - Harvard Bioscience, Inc. has entered into a $40 million credit facility agreement with BroadOak Capital Partners to refinance existing debt and strengthen its balance sheet [1][3] Financing Details - The credit facility consists of three term loans: Term Loan A and Term Loan B provide $32.5 million in gross proceeds, while Term Loan C is a $7.5 million convertible loan [2] - All loans mature on December 17, 2029, with quarterly principal amortization payments starting on December 31, 2027, for Term Loan A and Term Loan B [2] - BroadOak received warrants for 2 million shares at $0.50 per share and the right to nominate a board member [2] Strategic Importance - The financing package is seen as a significant milestone for the company, providing stability and flexibility for future operations [3] - The refinancing is expected to enhance liquidity and support the execution of strategic priorities [3] Board of Directors Update - Bill Snider from BroadOak has joined the board of directors and will serve on the compensation committee [4] - Snider brings over 30 years of investment experience in life sciences and has previously held significant roles in venture capital [4] Advisory Board Formation - A new Product, Operations, and Scientific Advisory Board will be established to guide commercial opportunities and product planning [5] Market Position and Future Outlook - Bill Snider expressed confidence in the company's position regarding new regulatory methodologies, indicating a strong future outlook [6]

Core Points - Former Treasury Secretary Larry Summers announced he is stepping back from all public commitments due to the fallout from his emails with Jeffrey Epstein [1][3] - Summers expressed deep shame and took full responsibility for his decision to continue communication with Epstein [1] - He will continue to fulfill his teaching obligations while reducing public engagements as part of a broader effort [2] Company and Industry Summary - Summers is a member of the board of OpenAI and a columnist for Bloomberg News, indicating his influence in both the technology and media sectors [2] - The release of Summers' emails with Epstein was part of a larger document disclosure by the House Oversight and Government Reform Committee, which included over 20,000 documents obtained from Epstein's estate [3] - Epstein's criminal background and subsequent death in 2019 have intensified scrutiny on individuals associated with him, impacting reputations and public roles [3]

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

Financial Performance - Revenues decreased by $1.4 million, or 6.3%, to $20.6 million for the three months ended September 30, 2025, compared to $22.0 million for the same period in 2024[86] - Gross profit decreased by $0.8 million, or 5.8%, to $12.0 million for the three months ended September 30, 2025, with a gross margin of 58.4%[87] - Revenues decreased by $6.8 million, or 9.7%, to $62.8 million for the nine months ended September 30, 2025, compared to $69.6 million for the same period in 2024[97] - Gross profit decreased by $5.1 million, or 12.3%, to $35.7 million for the nine months ended September 30, 2025, with a gross margin of 56.9%[98] Expenses - Sales and marketing expenses decreased by $0.9 million, or 16.4%, to $4.6 million for the three months ended September 30, 2025[88] - General and administrative expenses decreased by $0.8 million, or 17.2%, to $4.2 million for the three months ended September 30, 2025[89] - Research and development expenses decreased by $0.5 million, or 16.9%, to $2.1 million for the three months ended September 30, 2025[90] - Interest expense increased by $0.2 million, or 8.6%, to $2.6 million for the nine months ended September 30, 2025[105] Taxation - The effective tax rate for the three months ended September 30, 2025, was (8.6)%, compared to (6.9)% for the same period in 2024, primarily due to changes in income mix by jurisdiction[95] - The income tax benefit for the nine months ended September 30, 2025 was $(0.3) million, with an effective tax rate of 0.6%, compared to a benefit of $0.2 million and an effective tax rate of (1.4)% for the same period in 2024[107] Cash Flow and Liquidity - Cash and cash equivalents increased to $6.8 million as of September 30, 2025, up from $4.1 million as of December 31, 2024[108] - Net cash provided by operating activities was $6.8 million for the nine months ended September 30, 2025, compared to $(0.3) million for the same period in 2024, driven by a reduction in accounts receivable of $2.8 million and inventories of $1.6 million[115] - Net cash used in investing activities was $1.3 million for the nine months ended September 30, 2025, primarily for capital expenditures, compared to $0.9 million in 2024[116] - The company made $3.0 million in debt repayments on its term loan during the nine months ended September 30, 2025, resulting in net cash used in financing activities of $(3.7) million[117] - The company received ERTC refunds totaling $5.4 million as of September 30, 2025, contributing positively to cash flow[109] Compliance and Going Concern - The company was not in compliance with Refinancing Milestones and financial covenants as of June 30, 2025, leading to an amendment agreement with lenders to waive certain defaults[111] - The company continues to explore alternative sources of capital to refinance its outstanding indebtedness, but access to such capital remains uncertain[112] - There is substantial doubt about the company's ability to continue as a going concern unless it can access other sources of capital or extend repayment dates under the Credit Agreement[113] Other Financial Impacts - Goodwill impairment increased by $48.0 million for the nine months ended September 30, 2025, due to a sustained decrease in stock price and other factors[103] - The company recorded a loss on equity securities of $1.6 million from the sale of Harvard Apparatus Regenerative Technology Inc. stock, which was sold for $1.9 million during the nine months ended September 30, 2024[106]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $20.6 million, at the high end of guidance and slightly up from Q2 2025, but down from $22 million in Q3 2024 [4][11] - Gross margin improved to 58.4%, up from 58.1% in Q3 2024 and exceeded guidance of 56-58% [4][11] - Adjusted EBITDA increased to $2 million from $1.3 million in Q3 2024, driven by reduced operating expenses [11][15] - Operating cash flow was positive at $1.1 million for Q3 2025, contributing to a year-to-date cash flow of $6.8 million compared to negative $0.3 million in the same period last year [16][17] Business Line Data and Key Metrics Changes - Preclinical sales increased sequentially and year-over-year due to growth in telemetry and respiratory product lines [12][13] - The Soho telemetry rollout expanded into additional key accounts, with increased recurring consumable demand [5] - The Biochrome amino acid analyzer for bioproduction performed well, with expectations to exceed last year's consumable revenue [5] Market Data and Key Metrics Changes - Revenue in the Americas increased sequentially by 3.6% but was down 4.4% year-over-year [12] - European revenue increased 0.3% sequentially, reflecting stronger preclinical academic shipments, but was flat year-over-year [13] - In China, revenue was down 6.3% sequentially and 19.6% year-over-year, although there is optimism regarding tariff disruptions [9][13] Company Strategy and Development Direction - The company outlined three priorities for 2025: maintain financial discipline, accelerate product adoption, and strengthen capital structure through debt refinancing [4] - The launch of the Incubate MultiWell system aims to enhance the electrophysiology portfolio and expand into high-throughput applications [6][7] - The company is actively discussing options for refinancing its credit agreement, with expectations to complete this in Q4 2025 [8][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about increased demand and backlog heading into Q4 2025, with expectations for continued momentum [9][18] - The ongoing government shutdown may impact NIH funding distribution, which is being monitored closely [8][9] - The company is fundamentally stronger than at the beginning of the year, with a leaner structure and better alignment with long-term growth opportunities [9] Other Important Information - The company expanded its distribution agreement with Fisher Scientific, enhancing access to its products across North America [7] - The adoption of the MeshMEA organoid platform is gaining momentum, supported by regulatory initiatives [8] Q&A Session Summary Question: What drove the uptick in preclinical systems during the quarter? - The uptick was driven by broad demand for telemetry products across various regions and customer groups [20] Question: Is the backlog similar to the existing product mix? - The backlog showed a uniform increase across geographies and products, not driven by any specific product [21][22] Question: What improvements are seen in the academic and government market? - Improvement is reflected in Q3 results and strong backlog, but the potential impact of NIH funding and government shutdown is considered in guidance [23] Question: How does the guidance account for NIH funding and government shutdown? - The lower range of guidance considers the potential for a prolonged government shutdown affecting funding [27] Question: Will NIH funds flow through sales in the first quarter of next year if not released in Q4? - Funds are not lost but will be delayed, potentially impacting orders in Q1 or Q2 of 2026 [28] Question: What is the status of the ERP project? - The ERP project was completed in Q4, contributing to reduced expenses and operational efficiencies [30]

Financial Performance - Revenue for Q3 2025 was $20.6 million, at the high end of the $19-$21 million guidance range[7, 8] - Gross margin for Q3 2025 was 58.4%, exceeding the guidance range of 56%-58%[7, 8] - Adjusted EBITDA for Q3 2025 was $2.0 million, compared to $1.3 million in Q3 2024[7, 8] - Cash provided by operations was $6.8 million, up from ($0.3 million) in the same period last year[7] Regional Performance - APAC revenue decreased by 19.6% year-over-year, impacted by China tariffs[9] - EMEA revenue was relatively flat, down 0.6% year-over-year, influenced by macroeconomic instability[9] - Americas revenue decreased by 4.4% year-over-year, with a recovery in Pre-Clinical driven by NIH/ACA funding[9] Outlook and Strategy - The company is focused on refinancing or repaying the existing credit agreement in Q4 2025[7] - Q4 revenue is projected to range from $22.5 million to $24.5 million[17] - Q4 gross margin is expected to range from 58% to 60%[17]